Robert W. Baird Lowers Envista (NYSE:NVST) Price Target to $17.00

Envista (NYSE:NVST) had its target price lowered by equities researchers at Robert W. Baird from $19.00 to $17.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 4.62% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Evercore ISI reduced their target price on shares of Envista from $24.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, June 25th. Morgan Stanley lowered shares of Envista from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $33.00 to $21.00 in a research note on Friday, April 26th. The Goldman Sachs Group cut their price target on shares of Envista from $20.00 to $17.50 and set a “sell” rating on the stock in a report on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Tuesday, July 16th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Envista from $29.00 to $23.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.65.

Envista Stock Performance

NVST opened at $16.25 on Monday. The company has a 50-day moving average of $17.39 and a 200-day moving average of $20.14. Envista has a 1-year low of $15.69 and a 1-year high of $36.14. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 1.93.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business had revenue of $623.60 million for the quarter, compared to the consensus estimate of $634.85 million. During the same period in the prior year, the company earned $0.38 EPS. Envista’s quarterly revenue was down .6% on a year-over-year basis. As a group, analysts forecast that Envista will post 1.19 EPS for the current year.

Institutional Trading of Envista

Several large investors have recently modified their holdings of the company. Retirement Systems of Alabama boosted its holdings in Envista by 2.0% in the 4th quarter. Retirement Systems of Alabama now owns 504,572 shares of the company’s stock valued at $12,140,000 after purchasing an additional 10,120 shares during the period. Alberta Investment Management Corp increased its position in Envista by 41.7% in the 4th quarter. Alberta Investment Management Corp now owns 294,417 shares of the company’s stock valued at $7,084,000 after acquiring an additional 86,700 shares in the last quarter. Foundry Partners LLC acquired a new stake in Envista in the 4th quarter valued at about $3,571,000. Tweedy Browne Co LLC bought a new position in shares of Envista in the 1st quarter valued at about $21,053,000. Finally, Raymond James & Associates boosted its stake in shares of Envista by 820.6% in the 4th quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock valued at $9,822,000 after purchasing an additional 363,875 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.